Keith J. Kendall
2021
In 2021, Keith J. Kendall earned a total compensation of $2M as Chief Executive Officer at Aquestive Therapeutics, a 59% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $450,000 |
|---|---|
| Option Awards | $1,017,050 |
| Salary | $550,000 |
| Other | $32,148 |
| Total | $2,049,198 |
Kendall received $1M in option awards, accounting for 50% of the total pay in 2021.
Kendall also received $450K in non-equity incentive plan, $550K in salary and $32.1K in other compensation.
Rankings
In 2021, Keith J. Kendall's compensation ranked 5,959th out of 12,397 executives tracked by ExecPay. In other words, Kendall earned more than 51.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,959 out of 12,397 | 52nd |
Division Manufacturing | 2,519 out of 5,492 | 54th |
Major group Chemicals And Allied Products | 1,100 out of 2,367 | 54th |
Industry group Drugs | 980 out of 2,090 | 53rd |
Industry Pharmaceutical Preparations | 706 out of 1,537 | 54th |
Source: SEC filing on April 29, 2022.
Kendall's colleagues
We found two more compensation records of executives who worked with Keith J. Kendall at Aquestive Therapeutics in 2021.